Seek Returns

AVTR vs. BBIO: Avantor vs. BridgeBio Pharma Stock Comparison

How do Avantor (AVTR) and BridgeBio Pharma (BBIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and BridgeBio Pharma (BBIO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while BBIO is classified in Biotechnology.

Company profile comparison for Avantor (AVTR) and BridgeBio Pharma (BBIO)
Profile ItemAVTRBBIO
NameAvantor, Inc.BridgeBio Pharma Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization10.48 billion USD14.47 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateMay 17, 2019June 27, 2019
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

AVTR
BBIO
GSPC
Loading price history…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Avantor (AVTR) and BridgeBio Pharma (BBIO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Avantor (AVTR) and BridgeBio Pharma (BBIO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and BridgeBio Pharma (BBIO)
MetricAVTRBBIO
Total Return (1Y)36.41%22.70%
Total Return (3Y, Annualized)-5.02%40.97%
Total Return (5Y, Annualized)-16.62%8.25%

Risk Profile

Drawdown History

AVTR
BBIO
GSPC
Loading price history…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Avantor (AVTR) and BridgeBio Pharma (BBIO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and BridgeBio Pharma (BBIO)
MetricAVTRBBIO
Volatility (1Y, Annualized)43.39%44.39%
Beta (5Y)0.940.93
Max Drawdown (5Y)-82.42%-89.79%
Avg. Volume (3M)8.56M2.68M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AVTR and BBIO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and BridgeBio Pharma (BBIO)
MetricAVTRBBIO
Sharpe Ratio (1Y)0.740.41
Sortino Ratio (1Y)1.170.63

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Avantor (AVTR) earns 5.91% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max
109.18%
Q3
6.23%
AVTR
5.91%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
BBIO
--
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): BBIO does not report ROE, so it has no value marker; AVTR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Avantor (AVTR) reports 5.08%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max
18.05%
AVTR
5.08%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BBIO
-59.84%
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Avantor (AVTR) reports 8.19%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max
83.12%
Q3
14.77%
AVTR
8.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max
83.12%
Q3
14.77%
Median
0.00%
BBIO
-3.30%
Q1
-78.82%
Min
-207.40%
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and BridgeBio Pharma (BBIO)
MetricAVTRBBIO
ROE (TTM)5.91%--
ROA (TTM)2.83%-13.97%
Net Margin (TTM)5.08%-59.84%
Operating Margin (TTM)8.19%-3.30%
Gross Margin (TTM)31.59%94.34%

Growth

Revenue Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Avantor (AVTR) at -3.41% is in the bottom quartile, showing a clear gap in revenue momentum.

Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Avantor (AVTR) reports EPS growth of -175.00%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and BridgeBio Pharma (BBIO)
MetricAVTRBBIO
Revenue Growth (YoY)-3.41%126.26%
Revenue Growth (3Y CAGR)-4.46%86.30%
EPS Growth (YoY)-175.00%--
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Avantor (AVTR) at 1.89 and BridgeBio Pharma (BBIO) at 2.09 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AVTR
1.89
Min
0.10

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BBIO
2.09
Min
0.10
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Avantor (AVTR) carries debt-to-equity ratio of 0.63 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max
1.42
Q3
0.65
AVTR
0.63
Median
0.15
Q1
0.02
Min
0.00

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
BBIO
--
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): BBIO does not report debt-to-equity ratio, so it has no value marker; AVTR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and BridgeBio Pharma (BBIO)
MetricAVTRBBIO
Current Ratio (MRQ)1.892.09
Debt / Equity (MRQ)0.63--
Net Debt / EBITDA3.40--

Dividends

Dividend Yield (TTM)

Neither Avantor (AVTR) nor BridgeBio Pharma (BBIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Avantor (AVTR) nor BridgeBio Pharma (BBIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and BridgeBio Pharma (BBIO)
MetricAVTRBBIO
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Avantor (AVTR) trades at 30.94 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max
85.34
Q3
43.46
AVTR
30.94
Median
26.69
Q1
13.30
Min
0.07

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BBIO
--
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): BBIO does not report P/E ratio, so it has no value marker; AVTR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while BridgeBio Pharma (BBIO) at 15.31 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
AVTR
1.58
Min
0.01

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max
58.18
Q3
25.77
BBIO
15.31
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Avantor (AVTR) reports 1.80, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max
13.53
Q3
6.54
Median
3.25
AVTR
1.80
Q1
1.69
Min
-5.59

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BBIO
-5.59
Min
-5.59
Loading chart…
Avantor (AVTR) vs. BridgeBio Pharma (BBIO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and BridgeBio Pharma (BBIO)
MetricAVTRBBIO
P/E Ratio (TTM)30.94--
P/S Ratio (TTM)1.5815.31
P/B Ratio (MRQ)1.80-5.59
Free Cash Flow Yield (TTM)4.21%-1.98%